Dépôt DSpace/Manakin

Vaccine design from the ensemble of surface glycoprotein epitopes of SARS-CoV-2: An immunoinformatics approach

Afficher la notice abrégée

dc.rights.license CC BY eng
dc.contributor.author Rahman, N. cze
dc.contributor.author Ali, F. cze
dc.contributor.author Basharat, Z. cze
dc.contributor.author Shehroz, M. cze
dc.contributor.author Khan, M.K. cze
dc.contributor.author Jeandet, P. cze
dc.contributor.author Nepovimová, Eugenie cze
dc.contributor.author Kuča, Kamil cze
dc.contributor.author Khan, H. cze
dc.date.accessioned 2025-12-05T09:18:55Z
dc.date.available 2025-12-05T09:18:55Z
dc.date.issued 2020 eng
dc.identifier.issn 2076-393X eng
dc.identifier.uri http://hdl.handle.net/20.500.12603/1095
dc.description.abstract The present study aimed to work out a peptide-based multi-epitope vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We predicted different B-cell and T-cell epitopes by using the Immune Epitopes Database (IEDB). Homology modeling of the construct was done using SWISS-MODEL and then docked with different toll-like-receptors (TLR4, TLR7, and TLR8) using PatchDock, HADDOCK, and FireDock, respectively. From the overlapped epitopes, we designed five vaccine constructs C1–C5. Based on antigenicity, allergenicity, solubility, different physiochemical properties, and molecular docking scores, we selected the vaccine construct 1 (C1) for further processing. Docking of C1 with TLR4, TLR7, and TLR8 showed striking interactions with global binding energy of −43.48, −65.88, and −60.24 Kcal/mol, respectively. The docked complex was further simulated, which revealed that both molecules remain stable with minimum RMSF. Activation of TLRs induces downstream pathways to produce pro-inflammatory cytokines against viruses and immune system simulation shows enhanced antibody production after the booster dose. In conclusion, C1 was the best vaccine candidate among all designed constructs to elicit an immune response SARS-CoV-2 and combat the coronavirus disease (COVID-19). © 2020 by the authors. Licensee MDPI, Basel, Switzerland. eng
dc.format p. "Article number 423" eng
dc.language.iso eng eng
dc.publisher MDPI AG eng
dc.relation.ispartof Vaccines, volume 8, issue: 3 eng
dc.subject Allergenicity eng
dc.subject Antigenicity eng
dc.subject Coronavirus eng
dc.subject Multi-epitopes eng
dc.subject Pneumonia eng
dc.subject Vaccine eng
dc.title Vaccine design from the ensemble of surface glycoprotein epitopes of SARS-CoV-2: An immunoinformatics approach eng
dc.type article eng
dc.identifier.obd 43876767 eng
dc.identifier.doi 10.3390/vaccines8030423 eng
dc.publicationstatus postprint eng
dc.peerreviewed yes eng
dc.source.url https://www.mdpi.com/2076-393X/8/3/423 cze
dc.relation.publisherversion https://www.mdpi.com/2076-393X/8/3/423 eng
dc.rights.access Open Access eng


Fichier(s) constituant ce document

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Chercher dans le dépôt


Parcourir

Mon compte